Glaxosmithkline Pharma Share Price

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UKbased GSK Plc. a global biopharma company to unite science technology and talent to get ahead of disease together. The Company is headquartered in Mumbai and it has six branch offices a manufacturing facility at Nashik in Maharashtra 22 contract manufacturing organisations CMOs with regional and sales hubs across India. The Company is engaged interalia in the business of manufacturing distributing and trading in pharmaceuticals.The Companys portfolio includes General Medicines Vaccines and Specialty medicines that help prevent and treat disease. Their prescription medicines range across therapeutic areas such as AntiInfectives Dermatology Gynaecology Diabetes Oncology Cardiovascular Disease and Respiratory Diseases. They also offer a range of vaccines for the prevention of Hepatitis A Hepatitis B Invasive Disease caused by H Influenza Chickenpox Diphtheria Pertussis Tetanus Rotavirus Cervical Cancer and Others. They have two manufacturing units in India located at Nashik and Thane. Also they have a clinical development centre in Bangalore. GlaxoSmithKline Pharma Limited was incorporated in November 13 1924. During year 1956 the Company began primary production of vaccines at Worli. In the year 1960 the company started manufacturing Infant foods at milk drying plant at Aligarh. They also opened manufacturing facility for pharmaceuticals in Mumbai. In 1961 the Company started manufacturing Vitamin A and Betamethasone at new plant at Thane using imported raw materials. The Company registered as a limited company in the year 1968. Also they introduced the Animal health products. In the year 1971 the company built the Research development laboratory at Thane. Also they relocated the SmithKline French plant from Mumbai to Bangalore. In the year 1983 they commissioned the Nashik factory. SmithKline Beecham became a public limited company under the new name of Eskayef Ltd in the year 1984 and one new Plant was set up in Mysore for manufacture of bulk drugs. In the year 1985 the companys second basic drugs factory was inaugurated at Ankleshwar Gujarat. In the year 1986 the company launched joint venture projects Vegepro Foods and Feeds Ltd and K G Gluco Biols. The companys name was changed to Glindia Ltd in the year 1987. In the year 1988 the company commenced the production of bulk drug Ranitidine at Ankleshwar. Also they started a joint venture project with Hindustan Foods Ltd for the manufacture of extruded foods at Usgao Goa. In the year 1989 the company commenced their Zinetac production at Nashik. The companys name was changed from Glindia Ltd to Glaxo India Ltd. In the year 1990 the production of the bulk drug cephalexin was commenced at Ankleshwar and the salbutamol inhalers at Nashik. Glaxo rated amongst the first five of Indias most respected companies 4th place in a survey by Businessworld magazine. An agreement was signed with the Council of Scientific and Industrial Research CSIR during 1991. In the year 1992 the company sold their trade investments in Vegepro and Feeds Ltd. In the year 1993 they sold their investment in Hindustan Foods Ltd and Dempo Dairy Industries Ltd. Cetzine a secondgeneration antihistamine and research product of UCB Pharma Belgium was launched under a comarketing agreement. In the same year Glaxo received recognition from the Ministry of Commerce as an export house. In the year 1994 the company sold their Family Products Division to H J Heinz for a sum of Rs 210 crore. The Mysore plant received ISO 9002 certification and the new Iodex plant was inaugurated in Bangalore. In the year 1995 they inaugurated the government approved stateoftheart Pharmacy Research Development Centre PRD at Thane to cater to the unmet medical needs and to exploit local commercial opportunities.In the year 1998 the company acquired Biddle Sawyer Group of Companies which was struggled in the year before. In the year 2000 Agrivet Farm Care AFC tied up with Merial the worlds largest Animal Health Company to market poultry vaccines. The company ranked 6th in Business Today Stern Stewart Co. listing of Indias best Wealth Creator Companies and also the launched Seretide for Asthma. The merger of SmithKline Beecham Pharmaceuticals India Ltd into Glaxo India Limited was completed and the name of the company was changed to the present name GlaxoSmithKline Pharmaceuticals Ltd. Businessworld and the Indian Market Research Bureau IMRB named GlaxoSmithKline as Indias most respected Pharmaceutical Company in a survey in the year 2003. During the year the company launched Cetzine Cetirizine antihistamine Zimig terbinafine antiinfective CCM calcium citrate maleate nutritional Cobadex CZS multivitamin with trace elements.In the year 2004 the company launched Priorix measles mumps rubella vaccine. In the year 2005 the company launched oral contraceptives: Elogen desogestrel and ethinylestradiol and Zerogen progesterone only pill. They entered into the diabetes therapeutic segment with the launch of Windia rosiglitazone and Windamet rosiglitazone and metformin. In the year 2006 the company made an inlicensing alliance with Eisai Pharmaceuticals Japan and launched Parit rabeprazole gastrointestinal therapy area. Also GlaxoSmithKline divested their Agrivet Farm Care AFC animal health business. In the year 2007 the company launched Carzec carvedilol and Zemetril cefprozil.

Revenue: ₹979.94Cr as on September 2025 (Q2 FY26)
Net Profit: ₹257.49Cr as on September 2025 (Q2 FY26)
Listing date: 03 Nov, 1994
Chairperson Name: Renu S Karnad